Taipei, Taiwan, June 9th, 2023 -- Lotus Pharmaceutical Co., Ltd ("Lotus" or "the Company," Taiwan TWSE ticker: 1795) announces its unaudited consolidated revenues for May 2023, showcasing an exceptional growth rate of 51.8% compared to the corresponding period last year, reaching an impressive NT$1,321,517 thousand. Additionally, the Company's cumulative unaudited consolidated revenue for the first five months of 2023 has achieved a remarkable NT$7,862,593 thousand, reflecting a growth of 56.3% over the same period last year.
Lotus continues to excel in the Asian market with a consistent growth rate, witnessing an 18% increase compared to the previous year. Furthermore, the Company's export sales have soared by an extraordinary 150% this month when compared to the corresponding period last year. This outstanding performance can be attributed to the robust demand for Lenalidomide globally and the increased sales of buprenorphine/naloxone.
Excitingly, Lotus has received its first approval from Canadian health authorities for pomalidomide, a generic version of Pomalyst®. Pomalidomide is widely prescribed as a second-line treatment for multiple myeloma in patients who have previously undergone lenalidomide treatment. This approval strengthens Lotus' oncology product offering and positions the Company to commence the global commercialization of pomalidomide, starting with non-IP restricted markets.
Lotus Pharmaceutical remains dedicated to its expansion strategy in both the Asian and export markets. Concurrently, the Company is transitioning into a hybrid pharmaceutical player by expanding its generic business with a synergistic portfolio that includes Brands, 505(b)2s, and NCEs. The latest addition to Lotus' innovative portfolio is the in-licensing of global rights for NRX 101, indicated for the treatment of suicidal ideation in bipolar depression. In collaboration with Nasdaq-listed NRx Pharmaceuticals (NRXP) and US-based CNS specialist Almatica, a wholly owned subsidiary of Alvogen US, Lotus is committed to developing, manufacturing, and commercializing this potential breakthrough therapy that addresses this currently unmet medical need. NRX 101 is a fixed dose combination of D-Cycloserine and Lurasidone. Lurasidone, branded Latuda, had a global sales of over USD 4 billion in 2022.
Media Enquiries:
Susan Liao, IR/PR Director
+886 2 2700 5908